 |
|
|
|
 |
|
|
Nalidixic acid
|
|
Nalidixic acid
|
| Systematic (IUPAC) name |
| 1-ethyl-7-methyl-4-oxo-[1,8]naphthyridine-3-carboxylic acid |
| Identifiers |
| CAS number |
389-08-2 |
| ATC code |
J01MB02 |
| PubChem |
4421 |
| DrugBank |
APRD01133 |
| Chemical data |
| Formula |
C12H12N2O3 |
| Mol. mass |
232.235 g/mol |
| Pharmacokinetic data |
| Bioavailability |
? |
| Protein binding |
90% |
| Metabolism |
Partially Hepatic |
| Half life |
6-7 hours, significantly longer in renal impairment |
| Excretion |
? |
| Therapeutic considerations |
| Pregnancy cat. |
B U.S.
|
| Legal status |
|
| Routes |
Oral |
Nalidixic acid (tradenames Neggram® and Wintomylon®) is the basis for quinolone antibiotics.
Nalidixic acid is effective against both gram-positive and gram-negative bacteria. In lower concentrations, it acts bacteriostatically (that is, it inhibits growth and reproduction). In higher concentrations, it is bactericidal, meaning that it kills bacteria instead of merely inhibiting their growth.
It is especially used in treating urinary tract infections, caused for example by Escherichia coli, Proteus, Shigella, Enterobacter and Klebsiella.
See also
|
| |
|
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nalidixic_acid". A list of authors is available in Wikipedia.
|
|
|
|
|
|
Top